Table 1 Baseline characteristics of patients

Age (years)

Median (range)

60 (31–82)

62 (32–82)

57 (31–78)

67 (36–79)

58 (46–72)

< 70

142 (82.6%)

67 (79.8%)

47 (85.5%)

10 (66.7%)

15 (83.3%)

≥ 70

30 (17.4%)

17 (20.2%)

8 (14.5%)

5 (33.3%)

3 (16.7%)

Gender

Male

67 (39.0%)

31 (36.9%)

25 (45.5%)

6 (40.0%)

5 (27.8%)

Female

105 (61.0%)

53 (63.1%)

30 (54.5%)

9 (60.0%)

13 (72.2%)

Smoking status

Yes

37 (21.5%)

17 (20.2%)

16 (29.1%)

2 (13.3%)

2 (11.1%)

No

135 (78.5%)

67 (79.8%)

39 (70.9%)

13 (86.7%)

16 (88.9%)

ECOG PS

0–1

134 (77.9%)

64 (76.2%)

41 (74.5%)

14 (93.3%)

14 (77.8%)

2

38 (22.1%)

20 (23.8%)

14 (25.5%)

1 (6.7%)

4 (22.2%)

EGFR  mutation type

Deletion in exon 19

91 (52.9%)

46 (54.8%)

24 (43.6%)

9 (60.0%)

12 (66.7%)

21 L858R

72 (41.9%)

34 (40.4%)

29 (52.7%)

5 (33.3%)

4 (22.2%)

Others

9 (5.2%)

4 (4.8%)

2 (3.7%)

1 (6.7%)

2 (11.1%)

Neurologic symptoms

Yes

57 (33.1%)

24 (28.6%)

20 (36.4%)

6 (40.0%)

7 (38.9%)

No

115 (66.9%)

60 (71.4%)

35 (63.6%)

9 (60.0%)

11 (61.1%)

Cranial radiation

SRS

20 (11.6%)

8 (9.5%)

5 (9.1%)

4 (26.7%)

3 (16.7%)

WBRT

19 (11.0%)

9 (10.7%)

3 (5.5%)

3 (20.0%)

4 (22.2%)

No

133 (76.3%)

67 (79.8%)

47 (85.5%)

8 (53.3%)

11 (61.1%)

1st generation EGFR-TKIs

Gefitinib

123 (71.5%)

56 (66.7%)

41 (74.5%)

12 (80.0%)

14 (77.8%)

Icotinib

49 (28.5%)

28 (33.3%)

14 (25.5%)

3 (20.0%)

4 (22.2%)